LFG
FOLD

Larson Financial Group’s Amicus Therapeutics FOLD Stock Holding History

Larson Financial Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.39K Buy
373
+71
+24% +$1.02K ﹤0.01% 2571
2025
Q4 		$4.3K Sell
302
-487
-62% -$4.78K ﹤0.01% 2517
2025
Q3 		$6.22K Buy
789
+289
+58% +$2.06K ﹤0.01% 2271
2025
Q2 		$2.87K Buy
+500
New +$3.23K ﹤0.01% 2287
2025
Q1 		– Sell
-1,400
Closed -$13.2K – 3115
2024
Q4 		$13.2K Hold
1,400
– – ﹤0.01% 1386
2024
Q3 		$15K Buy
+1,400
New +$15.2K ﹤0.01% 1324
2023
Q4 		– Sell
-81
Closed -$985 – 1838
2023
Q3 		$985 Buy
+81
New +$1.04K ﹤0.01% 1494

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Larson Financial Group's FOLD Position: Q1 2026 in Review

Larson Financial Group increased its Amicus Therapeutics (FOLD) stake by 24% in Q1 2026, buying an estimated $1.02K and bringing the position to 373 shares worth $5.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2571.

Larson Financial Group first reported a position in FOLD in Q3 2023 and has held it in 7 quarters since. The position peaked at $15K in Q3 2024. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Larson Financial Group held 373 shares of Amicus Therapeutics worth $5.39K as of Q1 2026.
  • Larson Financial Group bought 71 Amicus Therapeutics shares in Q1 2026, an estimated $1.02K.
  • Amicus Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2571 holding.
  • Larson Financial Group first reported a position in Amicus Therapeutics in Q3 2023 and has held it in 7 quarters since.
  • Larson Financial Group's Amicus Therapeutics position peaked at $15K in Q3 2024.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.